Top

Published in:

Open Access 01-06-2011 | Original

Soluble CD40 ligand and prolactin levels in migraine patients during interictal period

Authors: Sibel Guldiken, Baburhan Guldiken, Muzaffer Demir, Levent Kabayel, Hulya Ozkan, Nilda Turgut, Remziye Hunkar, Selahattin Kat

Published in: The Journal of Headache and Pain | Issue 3/2011

Abstract

The relationship of migraine with cardiovascular diseases has been clarified by many studies, and currently, migraine is suggested to be a systematic vasculopathy. Inflammation, thrombosis and impaired vascular reactivity are the underlying pathophysiological mechanisms of the vasculopathy. In the present study, we aimed to investigate the relationship between prolactin levels and subclinical atherosclerosis risk factors such as soluble CD40 ligand (sCD40L) and high-sensitivity CRP (hsCRP) in migraine patients during interictal period. Fifty female migraine patients and age-matched 25 female control cases were enrolled in the study. Migraine diagnosis was settled according to the ICHD-II diagnostic criteria. A questionnaire was completed about the existence of vascular risk factors. Serum samples were used to measure sCD40L, hsCRP and prolactin levels. No difference was found between the prolactin levels of the migraine patients and the controls. The sCD40L levels were significantly higher in migraine patients (p < 0.001). High-sensitivity CRP levels showed no difference between the groups. There was no correlation between prolactin, sCD40L, and hs-CRP levels in migraine patients. We consider that the migraine patients are prone to subclinical atherosclerosis, but this tendency is independent of prolactin levels.

Tietjen GE (2009) Migraine as a systematic vasculopathy. Cephalalgia 29:989–996

D’Andrea G, Toldo M, Cortelazzo S, Milone FF (1982) Platelet activity in migraine. Headache 22:207–212, 6216226, 10.1111/j.1526-4610.1982.hed2205207.xCrossRefPubMed

Tietjen GE, Al Qasmi MM, Athanas K, Dafer RM, Khuder SA (2001) Increased von Willebrand factor in migraine. Neurology 57:334–336, 11468324, 1:STN:280:DC%2BD38%2Fis1ahsA%3D%3DCrossRefPubMed

Lee ST, Chu K, Jung KH, Kim DH, Kim EH, Choe VN, Kim JH, Im WS, Kang L, Park JE, Park HJ, Park HK, Song EC, Lee SK, Kim M, Roh JK (2008) Decreased number and function of endothelial progenitor cells in patients with migraine. Neurology 70:1510–1517, 18354079, 10.1212/01.wnl.0000294329.93565.94CrossRefPubMed

Gudmundsson LS, Aspelund T, Scher AI, Thorgeirsson G, Johannsson M, Launer LJ, Gudnason V (2009) C-reactive protein in migraine sufferers similar to that of non-migraineurs: the Reykjavik Study. Cephalalgia 29:1301–1310, 19438929, 10.1111/j.1468-2982.2009.01865.x, 1:STN:280:DC%2BD1MjktlGjtQ%3D%3DPubMedCentralCrossRefPubMed

Guldiken B, Guldiken S, Demir M, Turgut N, Kabayel L, Ozkan H, Ozcelik E, Tugrul A (2008) Insulin resistance and high sensitivity C-reactive protein in migraine. Can J Neurol Sci 35:448–451, 18973061CrossRefPubMed

Welch KM, Brandes AW, Salerno L, Brandes JL (2006) C-reactive protein may be increased in migraine patients who present with complex clinical features. Headache 46:197–199, 16492227, 10.1111/j.1526-4610.2006.00330.x, 1:STN:280:DC%2BD287gs1Sgtw%3D%3DCrossRefPubMed

Vanmolkot FH, de Hoon JN (2007) Increased C-reactive protein in young adult patients with migraine. Cephalalgia 27:843–846, 17668468, 10.1111/j.1468-2982.2007.01324.x, 1:STN:280:DC%2BD2svltVWqug%3D%3DCrossRefPubMed

Kurth T, Ridker PM, Buring JE (2008) Migraine and biomarkers of cardiovascular disease in women. Cephalalgia 28:49–56

10.

Liew G, Wang JJ, Mitchell P (2007) Migraine and coronary heart disease mortality: a prospective cohort study. Cephalalgia 4:368–371, 10.1111/j.1468-2982.2007.01298.xCrossRef

11.

Kurth T, Gaziano JM, Cook NR, Bubes V, Logroscino G, Diener HC, Buring JE (2007) Migraine and risk of cardiovascular disease in men. Arch Intern Med 167:795–801, 17452542, 10.1001/archinte.167.8.795CrossRefPubMed

12.

Agostoni E, Fumagalli L, Santoro P, Ferrarese C (2004) Migraine and stroke. Neurol Sci 25(Suppl 3):123–125, 10.1007/s10072-004-0268-6CrossRef

13.

Scher AI, Terwindt GM, Picavet HS, Verschuren WM, Ferrari MD, Launer LJ (2005) Cardiovascular risk factors and migraine: the GEM population-based study. Neurology 64:614–620, 15728281, 1:STN:280:DC%2BD2M%2FpvVyjsg%3D%3DCrossRefPubMed

14.

Ridker PM (2001) Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet 358:946–948, 11583743, 10.1016/S0140-6736(01)06112-8, 1:STN:280:DC%2BD3MrjsFenug%3D%3DCrossRefPubMed

15.

Schönbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268, 11696462, 10.1161/hc4401.099447CrossRefPubMed

16.

Prasad KS, Andre P, Yan Y, Phillips DR (2003) The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr Opin Hematol 10:356–361, 12913790, 10.1097/00062752-200309000-00006, 1:CAS:528:DC%2BD2cXkvFGksA%3D%3DCrossRefPubMed

17.

Bosco D, Belfiore A, Fava A, De Rose M, Plastino M, Ceccotti C, Mungari P, Iannacchero R, Lavano A (2008) Relationship between high prolactin levels and migraine attacks in patients with microprolactinoma. J Headache Pain 9:103–107, 18256782, 10.1007/s10194-008-0016-z, 1:CAS:528:DC%2BD1cXjvFKgtb8%3DPubMedCentralCrossRefPubMed

18.

Silberstein SD, Meriam GR (1993) Sex hormones and headache. J Pain Symptom Manage 8:98–114, 8492007, 10.1016/0885-3924(93)90107-7, 1:STN:280:DyaK3s3mtVaqsg%3D%3DCrossRefPubMed

19.

Fanciullacci M, Alessandri M, Del Rosso A (2000) Dopamine involvement in the migraine attack. Funct Neurol 15(Suppl 3):171–181, 11200788PubMed

20.

Headache Classification Sub-Committee of the International Headache Society (2004) International classification of headache disorders, 2nd edn. Cephalalgia 24:1–160

21.

Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML (2003) CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348:1104–1111, 12646667, 10.1056/NEJMoa022600, 1:CAS:528:DC%2BD3sXit1Smtbs%3DCrossRefPubMed

22.

Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schonbeck U (2003) Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108:1049–1052, 12912804, 10.1161/01.CIR.0000088521.04017.13, 1:CAS:528:DC%2BD3sXms1alur8%3DCrossRefPubMed

23.

Garlichs CD, Kozina S, Fateh-Moghadam S, Handschu R, Tomandl B, Stumpf C, Eskafi S, Raaz D, Schmeisser A, Yilmaz A, Ludwig J, Neundorfer B, Daniel WG (2003) Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 34:1412–1418, 12764232, 10.1161/01.STR.0000074032.64049.47, 1:CAS:528:DC%2BD3sXktVKms7w%3DCrossRefPubMed

24.

Unek IT, Bayraktar F, Solmaz D, Ellidokuz H, Sisman AR, Yuksel F, Yesil S (2010) The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people. Clin Med Res 8:89–95, 20660932, 10.3121/cmr.2010.889, 1:CAS:528:DC%2BC3cXhtFOrtLzLPubMedCentralCrossRefPubMed

25.

Guldiken S, Demir M, Arikan E, Turgut B, Azcan S, Gerenli M, Tugrul A (2007) The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res 119(1):79–84

26.

Neubauer H, Setiadi P, Günesdogan B, Pinto A, Börgel J, Mügge A (2010) Influence of glycaemic control on platelet bound CD40-CD40L system, P-selectin and soluble CD40 ligand in Type 2 diabetes. Diabet Med 27:384–390, 20536508, 10.1111/j.1464-5491.2010.02957.x, 1:CAS:528:DC%2BC3cXmslChsro%3DCrossRefPubMed

27.

Yuan M, Ohishi M, Wang L, Raguki H, Wang H, Tao L, Ren J (2010) Association between serum levels of soluble CD40/CD40 ligand and organ damage in hypertensive patients. Clin Exp Pharmacol Physiol 37:848–851, 20456428, 10.1111/j.1440-1681.2010.05368.x, 1:CAS:528:DC%2BC3cXhtVOht7zFCrossRefPubMed

28.

Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR (2002) Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106:896–899, 12186789, 10.1161/01.CIR.0000028962.04520.01CrossRefPubMed

29.

Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P (1997) Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 96:396–399, 9244201, 1:CAS:528:DyaK2sXltlShtbs%3DCrossRefPubMed

30.

Blake GJ, Ostfeld RJ, Yucel EK, Varo N, Schonbeck U, Blake MA, Gerhard M, Ridker PM, Libby P, Lee RT (2003) Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol 23:e11–e14, 12524242, 10.1161/01.ATV.0000050143.22910.62, 1:CAS:528:DC%2BD3sXhvFA%3DCrossRefPubMed

31.

Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U (2002) Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 277:25032–25039, 11978801, 10.1074/jbc.M204003200, 1:CAS:528:DC%2BD38XlsVWitLg%3DCrossRefPubMed

32.

Bath PM, Butterworth RJ (1996) Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 7:157–161, 8735807, 10.1097/00001721-199603000-00011, 1:CAS:528:DyaK28XjvFOrtro%3DCrossRefPubMed

33.

Sharp DB, Bath PMW, Martin JF, Martin JF, Beswick AD, Elwood PC (1995) Cigarette smoking sensitizes and desensitizes impedance-measured ADP-induced platelet aggregation in whole blood. Thromb Haemost 74:730–735, 8585014, 1:CAS:528:DyaK2MXnvFKqu74%3DPubMed

34.

Leira R, Sobrino T, Rodriguez-Yanez M, Blanco M, Arias S, Castillo J (2007) Mmp-9 immunoreactivity in acute migraine. Headache 47:698–702, 17501851, 10.1111/j.1526-4610.2006.00641.xCrossRefPubMed

35.

Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D (1995) Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 155:4917–4925, 7594496, 1:CAS:528:DyaK2MXptlejsL0%3DPubMed

36.

Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, Banchereau J (1994) Activation of human dendritic cells through CD40 cross-linking. J Exp Med 180:1263–1272, 7523569, 10.1084/jem.180.4.1263, 1:CAS:528:DyaK2cXlslOiurw%3DCrossRefPubMed

37.

Yellin MJ, Winikoff S, Fortune SM, Baum D, Crow MK, Lederman S, Chess L (1995) Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation. J Leukoc Biol 58:209–216, 7543921, 1:CAS:528:DyaK2MXns1Sms78%3DPubMed

38.

Galy AH, Spits H (1992) CD40 is functionally expressed on human thymic epithelial cells. J Immunol 149:775–782, 1378865, 1:CAS:528:DyaK3sXltFKkPubMed

39.

Sarchielli P, Alberti A, Baldi A, Coppola F, Rossi C, Pierguidi L, Floridi A, Calabresi P (2006) Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache 46:200–207, 16492228, 10.1111/j.1526-4610.2006.00337.xCrossRefPubMed

40.

de Carvalho JF, Hanaoka B, Szyper-Kravitz M, Shoenfeld Y (2007) C-Reactive protein and its implications in systemic lupus erythematosus. Acta Reumatol Port 32:317–322, 18159197PubMed

41.

Awaki E, Takeshima T, Takahashi K (1989) A neuroendocrinological study in female migraineurs: prolactin and thyroid stimulating hormone responses. Cephalalgia 9:187–193, 2507160, 10.1046/j.1468-2982.1989.0903187.x, 1:STN:280:DyaK3c%2FgtlWqtQ%3D%3DCrossRefPubMed

42.

Murialdo G, Martignoni E, De Maria A, Bonura ML, Sances G, Bono G, Polleri A (1986) Changes in the dopaminergic control of prolactin secretion and in ovarian steroids in migraine. Cephalalgia 6:43–49, 3698093, 10.1046/j.1468-2982.1986.0601043.x, 1:STN:280:DyaL287ovF2hsw%3D%3DCrossRefPubMed

43.

Peres MF, Sanchez del Rio M, Seabra ML, Tufik S, Abucham J, Cipolla-Neto J, Silberstein SD, Zukerman E (2001) Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry 71:747–751, 11723194, 10.1136/jnnp.71.6.747, 1:STN:280:DC%2BD3MnnslWhtg%3D%3DPubMedCentralCrossRefPubMed

44.

Ali Masoud S, Fakharian E (2005) Serum prolactin and migraine. Ann Saudi Med 25:489–491, 16438460PubMed

45.

Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, Lykka M, Kyrkou K, Rizos D, Creatsa M, Christodoulakos G, Alevizaki M, Sfikakis PP, Papamichael C (2009) Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 54:98–105, 19451414, 10.1161/HYPERTENSIONAHA.109.132100, 1:CAS:528:DC%2BD1MXntVyrtrg%3DCrossRefPubMed

46.

Serri O, Li L, Mamputu JC, Beuachamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol 64:336–370

47.

Leaños-Miranda A, Márquez-Acosta J, Cárdenas-Mondragón GM, Chinolla-Arellano ZL, Rivera-Leaños R, Bermejo-Huerta S, Romero-Arauz J, Alvarez-Jiménez G, Ramos-León J, Ulloa-Aguirre A (2008) Urinary prolactin as a reliable marker for preeclampsia, its severity, and the occurrence of adverse pregnancy outcomes. J Clin Endocrinol Metab 93:2492–2499, 18460570, 10.1210/jc.2008-0305CrossRefPubMed

48.

Reuwer AQ, Twickler MT, Hutten BA, Molema FW, Wareham NJ, Dallinga-Thie GM, Bogorad RL, Goffin V, Smink-Bol M, Kastelein JJ, Boekholdt SM, Khaw KT (2009) Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ Cardiovasc Genet 2:389–395, 20031611, 10.1161/CIRCGENETICS.109.853572, 1:CAS:528:DC%2BD1MXhtFCgtr%2FNCrossRefPubMed

49.

Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gözü H, Sezgin O, Haklar G, Akalin S (2003) Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 149:187–193, 12943520, 10.1530/eje.0.1490187, 1:CAS:528:DC%2BD3sXnsV2nu7k%3DCrossRefPubMed

Title: Soluble CD40 ligand and prolactin levels in migraine patients during interictal period
Authors: Sibel Guldiken
Baburhan Guldiken
Muzaffer Demir
Levent Kabayel
Hulya Ozkan
Nilda Turgut
Remziye Hunkar
Selahattin Kat
Publication date: 01-06-2011
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 3/2011
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1007/s10194-011-0306-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Soluble CD40 ligand and prolactin levels in migraine patients during interictal period

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

A 4-year follow-up of patients with medication-overuse headache previously included in a randomized multicentre study

Anxiety disorders in headache patients in a specialised clinic: prevalence and symptoms in comparison to patients in a general neurological clinic

Association between blood pressure measures and recurrent headache in adolescents: cross-sectional data from the HUNT-Youth study

Transient stabbing headache from an acute thalamic hemorrhage

One case of sporadic hemiplegic migraine with multiple pulmonary arteriovenous malformation

Effectiveness of an educational and physical program in reducing accompanying symptoms in subjects with head and neck pain: a workplace controlled trial